Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Related Posts

One-year outcomes of the RESILIA balloon-expandable transcatheter valve: survival, hemodynamics, and hypoattenuated leaflet thickening

Suruga K, Patel V, Guo Y, Shitan H, Ng D, Nagasaka T, Menda J, Singh A, Gheorghiu M, Patel D, Gupta A, Chakravarty T, Cheng[...]

Optimization of Image Quality for Quantitative Multi-Contrast Atherosclerosis Characterization (qMATCH): Comparison Between Transverse and Coronal Acquisitions

Hsu YC, Lu M, Llanes A, Keushkerian MJ, Nguyen KL, Johnson K, Altbach MI, Morris HD, DeMarco JK, Deshpande V, Mitsouras D, Saloner D, McNally[...]

Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US

Turagam MK, Aryana A, Day JD, Dukkipati SR, Hounshell T, Nair D, Natale A, Weiner S, Cheung JW, Chinitz L, Cuoco F, Daccarett M, Dandamudi[...]